{rfName}
At

Indexed in

License and use

Citations

8

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Romeo MAuthorBarretina Ginesta MpAuthorPardo BAuthor

Share

September 20, 2024
Publications
>
Article
No

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Publicated to:Journal Of Clinical Oncology. JCO2400668-JCO2400668 - 2024-09-18 (), DOI: 10.1200/JCO.24.00668

Authors: González-Martín A; Rubio MJ; Heitz F; Depont Christensen R; Colombo N; Van Gorp T; Romeo M; Ray-Coquard I; Gaba L; Leary A; De Sande LM; Lebreton C; Redondo A; Fabbro M; Barretina Ginesta M-P; Follana P; Pérez-Fidalgo JA; Rodrigues M; Santaballa A; Sabatier R; Bermejo-Pérez MJ; Lotz J-P; Pardo B; Marquina G; Sánchez-Lorenzo L; Quindós M; Estévez-García P; Guerra Alía E; Manso L; Casado V; Kommoss S; Tognon G; Henry S; Bruchim I; Oaknin A; Selle F

Affiliations

Arbeitsgemeinschaft Gynaekologische Onkologie (AGO), Wiesbaden, Germany. - Author
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium. - Author
Centre Leon Bérard and University of Lyon, Lyon, France. - Author
Department for Gynaecology and Gynaecologic Oncology, Kliniken Essen-Mitte, Essen, Germany. - Author
Division of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium. - Author
Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Paris, France. - Author
Grupo Español de Investigación en Cáncer ginecológicO (GEICO), Madrid, Spain. - Author
Gynecologic Oncology Department, Hillel Yaffe Medical Center, Affiliated with the Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. - Author
Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy. - Author
Mario Negri Gynecologic Oncology Group (MaNGO), Milan, Italy. - Author
Medical Oncology Department, Institut Català d'Oncologia, Institut Germans Trias i Pujol (IGTP), Badalona, Spain. - Author
Medical Oncology Department, Translational Oncology Group, CIMA, Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid, Spain. - Author
See more

Abstract

To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months. Patients were stratified by investigator-selected carboplatin doublet, TFIp, BRCA status, and PD-L1 status in de novo biopsy and randomly assigned 1:1 to receive either atezolizumab or placebo throughout standard therapy comprising six cycles of a carboplatin doublet followed (in patients with response/stable disease) by maintenance niraparib until progression. The primary end point was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Between November 2018 and January 2022, 417 patients were randomly assigned (15% BRCA-mutated, 36% PD-L1-positive, 66% TFIp >12 months, 11% previous poly [ADP-ribose] polymerase inhibitor after frontline CT, and 53% previous bevacizumab). Median follow-up was 28.6 months (95% CI, 26.6 to 30.5 months). Atezolizumab did not significantly improve PFS (hazard ratio, 0.89 [95% CI, 0.71 to 1.10]; P = .28). Median PFS was 11.2 months (95% CI, 10.1 to 12.1 months) with atezolizumab versus 10.1 months (95% CI, 9.2 to 11.2 months) with standard therapy. Subgroup analyses generally showed consistent results, including analyses by PD-L1 status. The objective response rate (ORR) was 45% (95% CI, 39 to 52) with atezolizumab and 43% (95% CI, 36 to 49) with standard therapy. The safety profile was as expected from previous experience of these drugs. Combining atezolizumab with CT and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve PFS or the ORR.

Keywords

Good health and well-being

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 6/322, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 20.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 20 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 22.9.
  • The number of mentions on the social network X (formerly Twitter): 25 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health and Well-Being, with a probability of 75% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; France; Germany; Israel; Italy; Luxembourg.